Ownership and insider activity for Innate Pharma S.A. (IPHA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections.
Price
| Price | $2.01 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | FR |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $175.9M | $99.4M | $152.3M | $202.9M | $136.8M | $103.8M | $84.2M | $70.6M | $66.4M | $28.1M |
| Short-term Investments | $21.8M | $16.7M | $15.2M | $16.0M | $14.8M | $16.1M | $17.3M | $21.9M | $14.4M | $6.2M |
| Receivables | $25.6M | $15.1M | $146.6M | $2.8M | $11.3M | $1.7M | $3.1M | $46.5M | $1.6M | $7.6M |
| Inventory | $513000 | $6.3M | 0 | $5.6M | $3.3M | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $230.1M | $137.5M | $319.6M | $237.6M | $173.3M | $138.3M | $139.8M | $148.0M | $85.7M | $46.7M |
| Property, Plant & Equipment | $9.1M | $10.7M | $10.2M | $11.7M | $11.7M | $10.2M | $8.5M | $6.3M | $5.1M | $4.4M |
| Goodwill | 0 | 0 | 0 | 0 | $1000 | $2000 | -$41.0M | 0 | 0 | 0 |
| Intangible Assets | $9.1M | $46.2M | $84.5M | $97.0M | $46.3M | $44.2M | $42.6M | $416000 | 0 | 0 |
| Total Assets | $281.6M | $255.0M | $451.2M | $401.4M | $307.4M | $267.5M | $207.9M | $175.2M | $111.1M | $62.7M |
| Accounts Payable | $15.6M | $20.0M | $28.6M | $27.9M | $20.7M | $14.7M | $13.7M | $8.6M | $7.9M | $15.0M |
| Short-term Debt | $375000 | $429000 | $394000 | $1.5M | $1.4M | $29.9M | $1.3M | $8.5M | $8.4M | $8.5M |
| Total Current Liabilities | $76.4M | $73.9M | $196.7M | $121.8M | $45.5M | $79.9M | $41.3M | $39.6M | $33.0M | $36.6M |
| Long-term Debt | $1.1M | $2.4M | $2.0M | $14.1M | $14.2M | $11.5M | $38.9M | $30.6M | $22.2M | $13.7M |
| Total Liabilities | $195.4M | $169.1M | $284.0M | $183.9M | $151.4M | $160.1M | $153.7M | $132.3M | $102.2M | $84.4M |
| Retained Earnings | -$103.6M | -$152.0M | -$134.8M | -$155.7M | -$220.5M | -$272.2M | -$330.3M | -$336.9M | -$386.4M | -$435.4M |
| Total Equity | $86.2M | $86.0M | $167.2M | $217.4M | $156.0M | $107.4M | $54.2M | $51.9M | $8.8M | -$21.7M |
| Total Debt | $5.3M | $5.9M | $4.5M | $18.7M | $19.1M | $44.3M | $42.3M | $39.9M | $31.0M | $22.6M |
| Net Debt | -$192.4M | -$110.2M | -$163.0M | -$200.1M | -$132.6M | -$75.6M | -$59.2M | -$52.6M | -$49.8M | -$11.7M |
| Working Capital | $153.6M | $63.6M | $122.9M | $115.8M | $127.8M | $58.4M | $98.5M | $108.4M | $52.8M | $10.1M |
Financial Health
| Debt / Equity | -1.04 |
| Current Ratio | 1.27 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -11.35 |
Profitability
| Return on Equity | 593.93% |
| Return on Invested Capital | -155.52% |
| Return on Assets | -78.41% |
| Gross Margin | 100.00% |
| Operating Margin | -2058.02% |
| Net Margin | -1764.51% |
Related companies: APLT · CGEN · CRBP · CRDF · CYBN · ELTX · MIST
Explore sector: Healthcare · Biotechnology
More sections of IPHA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks